Cidara Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025. During the meeting, stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the number of shares authorized for issuance by 2,880,000. Additionally, an amendment to the company's Amended and Restated Certificate of Incorporation was approved, increasing the authorized number of shares of Common Stock from 50,000,000 to 100,000,000. The stockholders also elected Jeffrey Stein, Ph.D., Bonnie Bassler, Ph.D., and Ryan Spencer as Class I Directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.